Mucopolysaccharidosis Type IV (Morquio Syndrome)
A rare inherited disorder of keratan sulfate breakdown that causes progressive skeletal dysplasia, short stature, and cervical spine instability, while intelligence typically remains normal. Coordinated orthopedic and cardiac monitoring is central to long-term care.
- Enzyme Replacement Therapy (Type IVA)
- Spinal Stability Monitoring
- Multidisciplinary Specialist Coordination
- Estimated Incidence
- ~1 in 200,000–300,000 births
- Inheritance Pattern
- Autosomal Recessive (GALNS or GLB1 gene)
- Typical Onset
- Early-to-mid childhood (1–3 years for Type A)
- Therapy Access
- Elosulfase alfa ERT (Type IVA)
Condition Overview
Mucopolysaccharidosis type IV (MPS IV), known as Morquio syndrome, is a rare inherited lysosomal storage disorder caused by deficiency of an enzyme involved in breaking down keratan sulfate. Unlike many other MPS types, intelligence is typically normal in Morquio syndrome, while the skeleton is severely and distinctively affected, leading to short stature, joint laxity, and a characteristic body shape.
There are two subtypes: Type IVA, caused by deficiency of N-acetylgalactosamine-6-sulfatase (GALNS gene), is the more common and generally more severe form. Type IVB, caused by deficiency of beta-galactosidase (GLB1 gene), tends to be milder and shares some clinical overlap with other beta-galactosidase deficiency disorders.
A particularly important feature of Morquio syndrome is instability of the upper cervical spine due to underdevelopment of the odontoid process, which can pose a serious risk of spinal cord injury if not identified and managed proactively.
Types and Subtypes
MPS IV is divided into two genetically distinct subtypes that differ in the deficient enzyme and typical severity.
Symptoms and Signs
Children with Morquio syndrome often appear normal at birth, with skeletal features becoming apparent in the first few years of life as growth slows and bone changes progress.
Causes and Risk Factors
MPS IV results from mutations in either the GALNS gene (Type IVA) or the GLB1 gene (Type IVB), both of which are required to break down keratan sulfate. Enzyme deficiency leads to progressive keratan sulfate accumulation, particularly in cartilage and the cornea.
Diagnosis and Investigations
Diagnosis combines characteristic skeletal findings on examination and imaging with biochemical and genetic confirmation.
Disease Phenotype and Severity Stratification
MPS IV does not use a tumor-staging framework. Disease severity is generally described along a spectrum based on age of onset and rate of skeletal and respiratory progression.
Standard Treatment Options
Treatment combines disease-modifying enzyme replacement therapy for Type IVA with proactive orthopedic, respiratory, and cardiac management to address the skeletal and organ complications common to both subtypes.
Advanced & Emerging Therapies
Beyond standard enzyme replacement therapy for Type IVA, research is exploring approaches to further improve skeletal and respiratory outcomes in Morquio syndrome.
Enzyme Replacement Therapy
Elosulfase alfa (recombinant GALNS)
Approved intravenous enzyme replacement for Type IVA that has demonstrated improvements in endurance testing and reduction of keratan sulfate excretion.
Precision Medicine
Gene therapy research
Early-stage gene-addition approaches for GALNS deficiency are being explored as a potential long-term alternative to repeated enzyme infusions.
Targeted
Optimized surgical spine stabilization techniques
Advances in pediatric cervical spine fusion and decompression techniques have improved outcomes for atlantoaxial instability in skeletal dysplasia patients.
Cellular Therapy
Hematopoietic stem cell transplant
Has been used in limited cases but is not considered standard given less consistent skeletal benefit compared to enzyme replacement therapy.
Biomarkers & Precision Diagnostics
Biochemical and genetic markers, along with skeletal and spine imaging, guide diagnosis, subtype classification, and ongoing monitoring in Morquio syndrome.
When a Second Opinion May Be Important
Given the surgical and procedural risks associated with cervical spine instability, a specialist second opinion is particularly valuable at key points in Morquio syndrome care.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in Morquio syndrome vary with subtype and severity, but with proactive orthopedic, cardiac, and respiratory management, many individuals live well into adulthood with normal intelligence, even as skeletal disease requires ongoing care.
Supportive Care and Living With MPS IVA
Supportive care in Morquio syndrome focuses heavily on protecting skeletal and spinal health while supporting mobility and overall function.
How CancerFax Helps You Explore Treatment Options
CancerFax helps individuals and families affected by Morquio syndrome access specialist review of medical reports, coordinate second opinions with skeletal dysplasia and metabolic disease specialists, and explore access to enzyme replacement therapy and emerging research programs.
Get a free case reviewFrequently Asked Questions
MPS IV, or Morquio syndrome, is a rare inherited disorder caused by deficiency of an enzyme needed to break down keratan sulfate, leading to progressive skeletal disease while intelligence typically remains normal.
Type IVA is caused by GALNS gene deficiency and is generally more common and more severe, while Type IVB, caused by GLB1 gene deficiency, tends to be milder with slower progression.
Early signs often include slowed growth, short stature, joint laxity, and characteristic chest and limb deformities becoming apparent in the first few years of life.
Diagnosis combines skeletal imaging, urine keratan sulfate testing, enzyme activity assays, and confirmatory genetic testing of the GALNS or GLB1 gene.
Elosulfase alfa enzyme replacement therapy is approved for Type IVA and can improve endurance and mobility. Orthopedic, cardiac, and respiratory management address the skeletal and organ complications.
Underdevelopment of the odontoid process can cause upper cervical spine instability, which carries a risk of spinal cord compression if not identified and managed proactively.
No. Unlike some other MPS types, intelligence is typically normal in Morquio syndrome, with the disease predominantly affecting the skeleton, cornea, and heart valves.
Yes. Both subtypes follow an autosomal recessive inheritance pattern, requiring both parents to carry a mutated copy of the relevant gene.
Care typically involves metabolic genetics, orthopedics, cardiology, pulmonology, ophthalmology, and physical therapy working together.
Yes. CancerFax can help coordinate medical report review, connect individuals and families with skeletal dysplasia and metabolic disease specialists for a second opinion, and explore access to enzyme replacement therapy and emerging research programs, including cross-border coordination where appropriate.
Get Specialist Guidance for Your Diagnosis
Connect with metabolic and genetic disease specialists, coordinate a second opinion, and explore therapy access options.